Apseloff G, Wilner K D, von Deutsch D A, Henry E B, Tremaine L M, Gerber N, Lazar J D
Department of Pharmacology, Ohio State University College of Medicine, Columbus 43210.
J Clin Pharmacol. 1992 Jul;32(7):643-6. doi: 10.1002/j.1552-4604.1992.tb05775.x.
An open-label, placebo-controlled study was conducted to determine the effects of sertraline on the steady-state levels and renal clearance of lithium in 20 healthy volunteers. Subjects received 600 mg of lithium twice daily for 9 days. On the evening of day 8, subjects received orally either placebo or 100 mg of sertraline; these were administered twice, 8 hours apart, beginning 2 hours after the evening dose of lithium. In a comparison of day 8 with day 9 (before administration of the morning doses of lithium), sertraline was associated with only a 0.01 mEq/L (1.4%) decrease in steady-state levels and a 0.11 L/hour (6.9%) increase in the renal clearance of lithium. Neither change was statistically significant relative to placebo. Four subjects were excluded from analysis because of protocol violations or laboratory abnormalities unrelated to sertraline. Seven subjects who received lithium plus sertraline experienced side effects, mainly tremors, possibly related to treatment, whereas none of those administered lithium plus placebo experienced side effects. No sertraline-related laboratory abnormalities were observed.
进行了一项开放标签、安慰剂对照研究，以确定舍曲林对20名健康志愿者体内锂的稳态水平和肾脏清除率的影响。受试者每天两次服用600毫克锂，持续9天。在第8天晚上，受试者口服安慰剂或100毫克舍曲林；这些药物在晚上服用锂剂2小时后开始，每隔8小时服用一次，共服用两次。在比较第8天和第9天（早晨服用锂剂之前）时，舍曲林仅使锂的稳态水平降低0.01 mEq/L（1.4%），使锂的肾脏清除率增加0.11 L/小时（6.9%）。相对于安慰剂，这两个变化均无统计学意义。4名受试者因违反方案或与舍曲林无关的实验室异常而被排除在分析之外。7名接受锂加舍曲林治疗的受试者出现了副作用，主要是震颤，可能与治疗有关，而接受锂加安慰剂治疗的受试者均未出现副作用。未观察到与舍曲林相关的实验室异常。
